Trials / Completed
CompletedNCT01265264
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 279 (actual)
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ulodesine and allopurinol combined for 12 weeks are effective in treating gout in patients who are not adequately responding to allopurinol alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ulodesine | Oral dose administered daily for 84 days. |
| DRUG | Placebo | Oral dose administered daily for 84 days. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-07-01
- Completion
- 2013-02-01
- First posted
- 2010-12-23
- Last updated
- 2013-11-20
Locations
54 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01265264. Inclusion in this directory is not an endorsement.